MedTrace Logo

CBD-Microglia PET Study

NCT04398719 · Status: COMPLETED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 28

Last updated 2026-04-29

No results posted yet for this study

Summary

This study aims to examine the effect of cannabidiol (CBD) pre-treatment on brain microglial activation in healthy human subjects. Secondarily, this study aims to examine the effect of cannabidiol (CBD) pre-treatment on central pain-sensitization in healthy human subjects.

Conditions

  • CBD
  • Healthy

Interventions

RADIATION

[11C]PBR28

The radiotracer, \[11C\]PBR28, will be administered at the beginning of each PET scan

DRUG

Low-dose lipopolysaccharide

Subjects will receive intravenous lipopolysaccharide.

DRUG

Intradermal Capsaicin

A small dose of capsaicin will be administered by intradermal injection.

Sponsors & Collaborators

  • National Center for Complementary and Integrative Health (NCCIH)

    collaborator NIH

  • Yale University

    lead OTHER

Principal Investigators

  • Mohini Ranganathan, MD · Yale University

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-05-07
Primary Completion
2024-12-11
Completion
2024-12-11
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04398719 on ClinicalTrials.gov